Table 2 Composition of the CLL cohort evolving TP53 mutation during the disease course, which underwent the telomere length measurements in multiple time points (n = 26)
From: Evolution of TP53 abnormalities during CLL disease course is associated with telomere length changes
Parameter | n (%) | |
|---|---|---|
Sex (female / male) | 12 / 14 (46.2% / 53.8%) | |
Median age at diagnosis | 57.7Â years | |
Median time to first treatment | 20.0Â months | |
IGHV status (mutated /unmutated) | 2 / 24 (7.7% / 92.3%) | |
| Â | baseline sample | follow-up sample |
Previously treated for CLL | 5 (19.2%) | 26 (100%) |
Hierarchical cytogenetics (FISH) | ||
 del(17p) | 3 (11.5%) | 10 (38.5%) |
 del(11q) | 10 (38.5%) | 9 (34.6%) |
 trisomy 12 | 3 (11.5%) | 2 (7.7%) |
 normal | 6 (23.1%) | 4 (15.4%) |
 del(13q) | 4 (15.4%) | 1 (3.8%) |
 Copy-neutral loss of heterozygosity 17p (n = 21) | 0 (0%) | 5 (23.8%) |
 Complex karyotype (≥ 3 changes; n = 24) | 7 (29.2%) | 9 (37.5%) |
 Highly complex karyotype (≥ 5 changes; n = 24) | 4 (16.7%) | 6 (25.0%) |
 ATM mutation > 10% VAF (n = 22) | 4 (15.4%) | 3 (12.5%) |
 TP53 mutation > 10% VAF | 3 (11.5%) | 26 (100%) |